source
- UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune diseaseUCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
- Celcuity reports positive Phase 3 data for gedatolisib, bolstering broader approval prospectsCelcuity announced new data from an ongoing Phase 3 trial of its experimental breast cancer drug gedatolisib. The data showed that two- and three-drug combinations that included gedatolisib delaye…